 Home > Active Ingredient News > Antitumor Therapy > Front Oncol: Efficacy and toxicity of three types of induction chemotherapy for locally advanced nasopharyngeal carcinoma: 10-year follow-up results

Front Oncol: Efficacy and toxicity of three types of induction chemotherapy for locally advanced nasopharyngeal carcinoma: 10-year follow-up results

 Last Update: 2021-10-20
 Source: Internet
 Author: User

Tags

ofloxacin ophthalmic solution 0.3 dosage

calcium chloride toxicity

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Currently, patients with locally advanced nasopharyngeal carcinoma usually use induction chemotherapy (IC) before concurrent radiotherapy (CRT)
.

The application of IC can improve the patients' distant metastasis-free survival (DMFS) and overall survival (OS)

Currently, patients with locally advanced nasopharyngeal carcinoma usually use induction chemotherapy (IC) before concurrent radiotherapy (CRT)

Enrollment mainly includes eligible patients with newly diagnosed stage III-IVA nasopharyngeal carcinoma
.

Propensity score matching (PSM) is used to balance prognostic covariates

Enrollment mainly includes eligible patients with newly diagnosed stage III-IVA nasopharyngeal carcinoma

A total of 855 patients were enrolled from April 2009 to December 2012 , of which 395 (46.

The 10-year OS, DFS (disease-free survival), DMFS and LFFS (survival without local treatment failure) rates in the overall population were 67.

Prognostic factors

Prognostic related factors Prognostic related factors

After PSM matching, the 10-year OS, DFS, DMFS, and LFFS rates of the TPF vs.
PF vs.
TP group were 68.
9% vs.
70.
3% vs.
60.
5% (P _{TPF vs.
TP} = 0.
83, P _{TPF vs.
PF} = 0.
068, P _{PF vs.
TP} = 0.
043), 64.
8% vs.
67.
6% vs.
59.
2% (P _{TPF vs.
TP} = 0.
585, P _{TPF vs.
PF} = 0.
219, P _{PF vs.
TP} = 0.
074), 79.
5 % vs.
79.
3% vs.
74.
5% (P _{TPF vs.
TP} = 0.
929, P _{TPF vs.
PF} = 0.
269, P _{PF vs.
TP} = 0.
310), and 81.
9% vs.
89.
7% vs.
81.
8% (P _{TPF vs.
.
TP} = 0.
039, P _{TPF vs.
PF} = 0.
784, P _{PF vs.
TP} = 0.
021)
.

The results of multivariate analysis showed that compared with PF + CRT, TPF + CRT (HR, 0.

After PSM matching, the 10-year OS, DFS, DMFS, and LFFS rates of the TPF vs.

Prognosis analysis after PSM

Sensitivity analysis found that, consistent with the above results, TPF + CRT and TP + CRT still achieved higher 10-year OS (70.
1% vs.
69.
3% vs.
60.
6%) and DFS (65.
7% vs.
66.
4) than PF + CRT.
% vs.
60.
2%) and DMFS (79.
8% vs.
78.
5% vs.
74.
4%) rates
.

Sensitivity analysis found that, consistent with the above results, TPF + CRT and TP + CRT still achieved higher 10-year OS (70.

Sensitive prognosis analysis

As expected, the PF regimen had the lowest incidence of grade 3-5 toxicity (27.
3%), and the TP regimen had the highest incidence of grade 3-5 toxicity, mainly including grade 3-5 neutropenia (97.
1%) and fever.
Decreased neutrophils (11.
8%)
.

In addition, grade 3-5 non-hematological toxicity in the TP group is uncommon

As expected, the PF regimen had the lowest incidence of grade 3-5 toxicity (27.

Comparison of adverse reactions

In summary, studies have shown that for patients with stage III-IVA NPC, TPF+CRT and TP+CRT improve the 10-year OS of patients compared with PF+CRT
.

In summary, studies have shown that for patients with stage III-IVA NPC, TPF+CRT and TP+CRT improve the 10-year OS of patients compared with PF+CRT
.
Studies have shown that for patients with stage III-IVA NPC, TPF+CRT and TP+CRT improve the 10-year OS of patients compared with PF+CRT
.
Studies have shown that for patients with stage III-IVA NPC, TPF+CRT and TP+CRT improve the 10-year OS of patients compared with PF+CRT
.

Original source:

Peng H, Chen B, He S, Tian L and Huang Y (2021) Efficacy and Toxicity of Three Induction Chemotherapy Regimens in Locoregionally Advanced Nasopharyngeal Carcinoma: Outcomes of 10-Year Follow-Up.
Front.
Oncol.
11:765378.
doi: 10.
3389/fonc.
2021.
765378

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.